- Home
- AVIR vs RNAC Comparison
AVIR vs RNAC Comparison
Compare AVIR & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- RNAC
- Stock Information
- Founded
- AVIR 2012
- RNAC 2007
- Country
- AVIR United States
- RNAC United States
- Employees
- AVIR N/A
- RNAC N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- RNAC Biotechnology: Pharmaceutical Preparations
- Sector
- AVIR Health Care
- RNAC Health Care
- Exchange
- AVIR Nasdaq
- RNAC Nasdaq
- Market Cap
- AVIR 273.7M
- RNAC 291.7M
- IPO Year
- AVIR 2020
- RNAC 2016
- Fundamental
- Price
- AVIR $2.55
- RNAC $9.98
- Analyst Decision
- AVIR Hold
- RNAC Strong Buy
- Analyst Count
- AVIR 1
- RNAC 7
- Target Price
- AVIR $6.00
- RNAC $41.00
- AVG Volume (30 Days)
- AVIR 532.5K
- RNAC 78.7K
- Earning Date
- AVIR 05-12-2025
- RNAC 05-08-2025
- Dividend Yield
- AVIR N/A
- RNAC N/A
- EPS Growth
- AVIR N/A
- RNAC N/A
- EPS
- AVIR N/A
- RNAC N/A
- Revenue
- AVIR N/A
- RNAC $34,173,000.00
- Revenue This Year
- AVIR N/A
- RNAC N/A
- Revenue Next Year
- AVIR N/A
- RNAC N/A
- P/E Ratio
- AVIR N/A
- RNAC N/A
- Revenue Growth
- AVIR N/A
- RNAC 31.91
- 52 Week Low
- AVIR $2.60
- RNAC $8.85
- 52 Week High
- AVIR $4.15
- RNAC $41.87
- Technical
- Relative Strength Index (RSI)
- AVIR 37.12
- RNAC 38.68
- Support Level
- AVIR $2.66
- RNAC $9.51
- Resistance Level
- AVIR $3.01
- RNAC $11.23
- Average True Range (ATR)
- AVIR 0.15
- RNAC 0.96
- MACD
- AVIR -0.03
- RNAC -0.04
- Stochastic Oscillator
- AVIR 7.02
- RNAC 13.09
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.